uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Gadobenate dimeglumine-enhanced magnetic resonance angiography of the pelvic arteries
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Radiology, Oncology and Radiation Science, Radiology.
Show others and affiliations
2003 (English)In: Investigative Radiology, ISSN 0020-9996, E-ISSN 1536-0210, Vol. 38, no 8, 504-515 p.Article in journal (Refereed) Published
Abstract [en]


To evaluate 4 doses of gadobenate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (CE-MRA) of the pelvic arteries and to compare CE-MRA with unenhanced time-of-flight MRA (2D-TOF-MRA).


A multicenter Phase II dose-finding study was performed in 136 patients with Gd-BOPTA doses of 0.025, 0.05, 0.1, and 0.2 mmol/kg bodyweight. Evaluation of CE-MRA images and comparison with 2D-TOF-MRA images was performed onsite and by 2 blinded offsite reviewers in terms of subjective image quality, number of lesions detected, and confidence in lesion characterization.


Significant (P < 0.05) improvements over unenhanced findings were observed for CE-MRA at all dose levels. For reviewer 1 and the onsite investigators, the overall image quality increased up to a dose of 0.1 mmol/kg and then plateaued. For reviewer 2, increased image quality was noted up to a dose of 0.2 mmol/kg. Significant (P < 0.005) increases in diagnostic confidence on CE-MRA versus unenhanced MRA was observed for all dose groups by reviewer 1 and the onsite investigators and for the 0.1 and 0.2 mmol/kg dose groups by reviewer 2. No serious adverse events were recorded that were attributable to the study drug and no trends in laboratory parameters, vital signs, or electrocardiogram recordings were observed.


Gadobenate dimeglumine-enhanced MRA is safe and significantly more effective than unenhanced 2D-TOF-MRA for imaging the pelvic arteries. A dose of 0.1 mmol/kg appears the most appropriate dose for subsequent Phase III clinical evaluation.

Place, publisher, year, edition, pages
2003. Vol. 38, no 8, 504-515 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-153067DOI: 10.1097/01.rli.0000074585.46615.2ePubMedID: 12874517OAI: oai:DiVA.org:uu-153067DiVA: diva2:415052
Available from: 2011-05-05 Created: 2011-05-05 Last updated: 2011-10-14Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
In the same journal
Investigative Radiology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 153 hits
ReferencesLink to record
Permanent link

Direct link